NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma.
Steven J M JonesLaura M WilliamsonJames T TophamMichael Kuan-Ching LeeAngela GoytainJulie HoRobert E DenrocheGunHo JangErin PleasanceYaoquing ShenJoanna M KarasinskaJohn P McGhieSharlene GillHoward J LimMalcolm J MooreHui-Li WongTony NgStephen YipWei ZhangSara SadeghiCaralyn ReisleAndrew J MungallRichard A MooreYussanne MaJennifer J KnoxSteven GallingerJanessa LaskinMarco A MarraDavid F SchaefferDaniel J RenoufPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
This work adds to a growing body of evidence that NRG1 gene fusions are recurrent, therapeutically actionable genomic events in pancreatic cancers. Based on the clinical outcomes described here, patients with KRAS wild-type tumors harboring NRG1 gene fusions may benefit from treatment with afatinib.See related commentary by Aguirre, p. 4589.